KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 148 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,274 | -29.6% | 35,279 | -5.9% | 0.00% | – |
| Q2 2023 | $67,107 | -90.8% | 37,490 | -80.0% | 0.00% | -100.0% |
| Q1 2023 | $729,181 | -50.4% | 187,450 | -56.6% | 0.00% | -50.0% |
| Q4 2022 | $1,469,745 | +73.1% | 432,278 | +178.1% | 0.01% | +33.3% |
| Q3 2022 | $849,000 | +310.1% | 155,433 | +238.1% | 0.01% | +500.0% |
| Q2 2022 | $207,000 | -40.2% | 45,978 | -20.3% | 0.00% | -50.0% |
| Q2 2019 | $346,000 | -54.8% | 57,681 | -56.0% | 0.00% | -60.0% |
| Q1 2019 | $765,000 | +213.5% | 130,956 | +379.7% | 0.01% | +150.0% |
| Q1 2016 | $244,000 | -55.2% | 27,300 | -33.6% | 0.00% | -60.0% |
| Q4 2015 | $545,000 | +29.1% | 41,100 | +2.6% | 0.01% | +66.7% |
| Q3 2015 | $422,000 | -66.0% | 40,075 | -12.3% | 0.00% | -72.7% |
| Q2 2015 | $1,243,000 | -7.9% | 45,700 | +3.6% | 0.01% | 0.0% |
| Q1 2015 | $1,350,000 | +227.7% | 44,100 | +300.9% | 0.01% | +266.7% |
| Q4 2014 | $412,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |